UCB (EBR:UCB) UCB Media Room: Evenity European Commission Approval

Directive transparence : information réglementée

12/12/2019 07:01
https://u7061146.ct.sendgrid.net/wf/click?upn=3DG62jSYfZdO-2F12d8lSllQBx1W2= 7HkUdGSImvHQ6HnxefH6vFiGPeqeb84i0MpatjMWGK-2FMPeH-2B9kAbjTGxObA7IhIz0IptKYi= cnRWpQWXJdryTTA-2Fl3-2BsVlPddMZ4Cnvj_-2B-2Ft0TnE1oEbVIWS8vHM8JK8eu8RpJ4re5B= wmFRw6Tr0XlsWOeqQqZTjzwcPKItQR0hTxd9ZQ7rBLYSOuAKeTefElHQ9EZfLoWbvi8z1TsABlR= 759s4J2EhtSfn3pHAUtByXw7JC3JPLCZWALTfp2qB8ybKI-2BIfr9CYvKg-2FmYTIW0h1mkdOSt= Ee585hP9OLwIBCqoYPYNvvVTHJplwfHevNzGuk6gyVVeGGWcrOovFkiNmsxeb1fazEQgG47sy3t= DGXpU-2FDSpmHI4qJQKYJ8edsoHTdlU4rEITBm7HKU6XoT4j6ROjA1gbJq55aE2Ic27VIynt1zG= 65Y3hhiXd0YSL6tFBbUH94RWugyJjviObUI-3D ** European Commission Approves EVENITY^=C2=AE (Romosozumab) for the Treatm= ent of Severe Osteoporosis in Postmenopausal Women at High Risk of Fracture ------------------------------------------------------------ =C2=B7 First new osteoporosis medicine approved in the European Union (EU) = since 2010 =C2=B7 Novel bone-builder with a dual effect that both increases bone forma= tion and reduces bone loss Brussels, Belgium and Thousand Oaks, Calif (December 12, 2019) =E2=80=93 UC= B (Euronext Brussels: UCB) and Amgen (NASDAQ:AMGN) today announced that the= European Commission (EC) has granted marketing authorization for EVENITY= =C2=AE (romosozumab) for the treatment of severe osteoporosis in postmenopa= usal women at high risk of fracture. Romosozumab is a novel bone-builder wi= th a dual effect that increases bone formation and to a lesser extent reduc= es bone resorption (or bone loss).=C2=A0 =E2=80=9CToday=E2=80=99s European population is living longer and expecting= more out of life in their later years. Yet fragility fractures, due to ost= eoporosis, affect 1 in 3 women aged over 50, and evidence shows that many w= omen remain undiagnosed and untreated following a fracture. These fractures= represent a barrier to healthy aging, potentially impacting independence a= nd quality of life,^1=E2=80=9D said Dr. Pascale Richetta, head of bone and = executive vice president, UCB. =E2=80=9CWith today=E2=80=99s approval of ro= mosozumab we can now offer patients and clinicians a new medicine that can = help drive positive changes in secondary fracture prevention.=E2=80=9D The approval follows a positive opinion from the Committee for Medicinal Pr= oducts for Human Use (CHMP) that was received in October 2019. The first la= unches of romosozumab in the European Economic Area (EEA) are planned for t= he first half of 2020. As the population ages, the incidence and contribution of fragility fractur= es to the overall healthcare spend in Europe will continue to rise. Recent = studies estimate that every year =E2=82=AC37 billion is spent on healthcare= costs for the 2.7 million fragility fractures that occur across the EU6 na= tions of France, Germany, Italy, Spain, Sweden, and the UK.^1 This annual e= xpenditure is predicted to increase to over =E2=82=AC47 billion by 2030.^1= =C2=A0 =E2=80=9CAfter her first fracture, a woman is five times more likely to suf= fer another fracture within a year.^2 Romosozumab is a significant step for= ward in the management of osteoporosis for physicians who need to treat pat= ients with a medicine that can rapidly increase bone mineral density within= 12 months,=E2=80=9D said David M. Reese, M.D., executive vice president of= Research and Development at Amgen. =E2=80=9CWe are pleased by the European= Commission=E2=80=99s approval to make this therapy available to the millio= ns of women at high risk of fracture in the European Union.=E2=80=9D =E2=80=9CFragility fractures can often be avoided but their prevention and = management are being neglected despite a large personal, societal and econo= mic impact. With the number of worldwide fractures expected to rise there i= s a growing need to take action and prioritise post-fracture care through b= etter education, specialist services, lifestyles and medicines,=E2=80=9D sa= id Alison Doyle, head of clinical operations for the Royal Osteoporosis Soc= iety. =E2=80=9CTherefore, we welcome this approval as it represents a new t= herapeutic option for both patients and health care professionals in addres= sing this neglected condition.=E2=80=9D European Commission marketing authorization approval is valid in all Europe= an Union (EU) and EEA-European Free Trade Association (EFTA) states (Norway= , Iceland, and Liechtenstein). Romosozumab is now approved in 37 countries,= including the U.S.,=C2=A0Japan, Canada=C2=A0and Australia. References 1. International Osteoporosis Foundation. Broken Bones, Broken Lives: A Roa= dmap to Solve the Fragility Fracture Crisis in Europe. https://u7061146.ct.= sendgrid.net/wf/click?upn=3DrxX2Bk4zIZ5OmFHb0keB36Hy70YUUs86vOuNRQXl62O4G9M= tBwfPOfrvGSC1kfjiJJ9IN9LbGF6Oi9L4F-2FLLjOzMM0T5h4YHzKQxMdxNdtM-3D_-2B-2Ft0T= nE1oEbVIWS8vHM8JK8eu8RpJ4re5BwmFRw6Tr0XlsWOeqQqZTjzwcPKItQR0hTxd9ZQ7rBLYSOu= AKeTefElHQ9EZfLoWbvi8z1TsABlR759s4J2EhtSfn3pHAUtByXw7JC3JPLCZWALTfp2qB8ybKI= -2BIfr9CYvKg-2FmYTIW0h1mkdOStEe585hP9OLwIBCqoYPYNvvVTHJplwfHevEq3Jm1dF1YsWL= Z1ehdrbMZmTtTjKiVkL62HrTcLubsI8BtPl8zfxJ2IHUkZH5hrz7TlRcYA-2B-2FilwBhpJfxYj= zK3pBrk0JYEYx-2BlgBUiUGnEoER-2BJmLrI6am94OxZOFYdtq7Al0-2FdZjSfYrJHPTS7DY-3D= (November 2019). 2. Lindsay R, Silverman SL, Cooper C, et al. Risk of new vertebral fracture= in the year following fracture. JAMA. 2001;285(3):320-323. About EVENITY^=C2=AE (romosozumab) Romosozumab is a bone-forming monoclonal antibody. It is designed to work b= y inhibiting the activity of sclerostin, which simultaneously results in in= creased bone formation and to a lesser extent decreased bone resorption. Th= e romosozumab development program includes 19 clinical studies that enrolle= d approximately 14,000 patients. Romosozumab has been studied for its poten= tial to reduce the risk of fractures in an extensive global Phase 3 program= that included two large fracture trials comparing romosozumab to either pl= acebo or active comparator in over 11,000 postmenopausal women with osteopo= rosis. Amgen and UCB are co-developing romosozumab. Important Safety Information about EVENITY^=C2=AE (romosozumab) in the EU/E= EA In the EU, Romosozumab is indicated for treatment of severe osteoporosis in= postmenopausal women at high risk of fracture. Contraindications: Romosozu= mab is contraindicated in patients who are allergic to romosozumab or any o= f the excipients, who have low levels of calcium in the blood (hypocalcaemi= a), or who have a history of myocardial infarction (heart attack) or stroke= . Myocardial infarction or stroke: Heart attack and stroke have been report= ed in patients receiving Romosozumab in randomised controlled trials (uncom= mon). Treatment with Romosozumab should not be initiated in patients with a= history of heart attack or stroke. When determining whether to use Romosoz= umab for an individual patient, the presence of risk factors for cardiovasc= ular problems, including established cardiovascular disease, high blood pre= ssure, high blood fat levels, diabetes, smoking or kidney problems, should = be evaluated. Romosozumab should only be used if the prescriber and patient= agree that the benefit outweighs the risk. If a patient experiences a myoc= ardial infarction or stroke during therapy, treatment with Romosozumab shou= ld be discontinued. Hypocalcaemia: Transient hypocalcaemia has been observe= d in patients receiving Romosozumab. Hypocalcaemia should be corrected prio= r to initiating therapy with Romosozumab and patients should be monitored f= or signs and symptoms of hypocalcaemia. If any patient presents with suspec= ted symptoms of hypocalcaemia during treatment, calcium levels should be me= asured. Patients should be adequately supplemented with calcium and vitamin= D. Patients with severe renal impairment (estimated glomerular filtration = rate [eGFR] 15 to 29ml/min/1.73m2) or receiving dialysis are at greater ris= k of developing hypocalcaemia and the safety data for these patients are li= mited. Calcium levels should be monitored in these patients. Hypersensitivi= ty: Clinically significant hypersensitivity reactions, including angioedema= , erythema multiforme, and urticaria occurred in the Romosozumab group in c= linical trials. If an anaphylactic or other clinically significant allergic= reaction occurs, appropriate therapy should be initiated and use of Romoso= zumab should be discontinued. Osteonecrosis of the Jaw: Osteonecrosis of th= e jaw (ONJ) has been reported rarely in patients receiving Romosozumab. The= following risk factors should be considered when evaluating a patient=E2= =80=99s risk of developing ONJ: (1) potency of the medicinal product that i= nhibits bone resorption (the risk increases with the antiresorptive potency= of the compound), and cumulative dose of bone resorption therapy, (2) canc= er, co-morbid conditions (e.g. anaemia, coagulopathies, infection), smoking= , (3) concomitant therapies: corticosteroids, chemotherapy, angiogenesis in= hibitors, radiotherapy to head and neck, (4) poor oral hygiene, periodontal= disease, poorly fitting dentures, history of dental disease, invasive dent= al procedures e.g. tooth extractions. All patients should be encouraged to = maintain good oral hygiene and receive routine dental check-ups. Dentures s= hould fit correctly. Patients under dental treatment, or who will undergo d= ental surgery (e.g. tooth extractions) whilst being treated with Romosozuma= b should inform their doctor about their dental treatment and inform their = dentist that they are receiving Romosozumab. Patients should immediately re= port any oral symptoms such as dental mobility, pain or swelling or non-hea= ling of sores or pus discharge during treatment with Romosozumab. Patients = who are suspected of having or who develop ONJ while receiving Romosozumab = should receive care by a dentist or an oral surgeon with expertise in ONJ. = Discontinuation of Romosozumab therapy should be considered until the condi= tion resolves and contributing risk factors are mitigated where possible. A= typical Femoral Fractures: Atypical low-energy or low trauma fracture of th= e femoral shaft, which can occur spontaneously, has been reported rarely in= patients receiving Romosozumab. Any patient who presents with new or unusu= al thigh, hip, or groin pain should be suspected of having an atypical frac= ture and should be evaluated to rule out an incomplete femur fracture. Pati= ent presenting with an atypical femur fracture should also be assessed for = symptoms and signs of fracture in the contralateral limb. Interruption of R= omosozumab therapy should be considered, based on an individual benefit-ris= k assessment. Adverse Reactions: The most common adverse reactions were nas= opharyngitis (13.6%) and arthralgia (12.4%). Common adverse reactions inclu= ded hypersensitivity, sinusitis, rash, dermatitis, headache, neck pain, mus= cle spasms and injection site reactions (most frequent injection site react= ions were pain and erythema). Uncommon adverse reactions were urticaria, hy= pocalcaemia, stroke, myocardial infarction and cataract. Finally, rare side= effects were serious allergic reactions which caused swelling of the face,= throat, hands, feet, ankles or lower legs (angioedema) and acute skin erup= tion (erythema multiforme). Refer to the attached European Summary of Product Characteristics for other= adverse reactions and full prescribing information for EVENITY^=C2=AE=E2= =96=BC. =E2=96=BC This medicinal product is subject to additional monitoring. About the Amgen and UCB Collaboration Since 2004, Amgen and UCB have been working together under a collaboration = and license agreement to research, develop and market antibody products tar= geting the protein sclerostin. As part of this agreement, the two companies= continue to collaborate on the development of romosozumab for the treatmen= t of osteoporosis. This gene-to-drug project demonstrates how Amgen and UCB= are joining forces to translate a genetic discovery into a new medicine, t= urning conceptual science into a reality. CONTACT: UCB, Brussels Scott Fleming, Bone Communications, UCB, T +44 7702777378, scott.fleming@uc= b.com Laurent Schots, Media Relations, UCB, T+32.2.559.92.64, laurent.schots@ucb.= com Antje Witte, Investor Relations, UCB, T +32.2.559.94.14, antje.witte@ucb.com Isabelle Ghellynck, Investor Relations, UCB, T+32.2.559.9588, isabelle.ghel= lynck@ucb.com CONTACT: Amgen, Thousand Oaks Jessica Akopyan, 805-447-0974 (media)=C2=A0 Trish Hawkins, 805-447-5631 (media) Arvind Sood, 805-447-1060 (investors) About UCB UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company = focused on the discovery and development of innovative medicines and soluti= ons to transform the lives of people living with severe diseases of the imm= une system or of the central nervous system. With 7 500 people in approxima= tely 40 countries, the company generated revenue of =E2=82=AC 4.6 billion i= n 2018. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twit= ter: @UCB_news. UCB Forward-Looking Statements This press release contains forward-looking statements based on current pla= ns, estimates and beliefs of management. All statements, other than stateme= nts of historical fact, are statements that could be deemed forward-looking= statements, including estimates of revenues, operating margins, capital ex= penditures, cash, other financial information, expected legal, political, r= egulatory or clinical results and other such estimates and results. By thei= r nature, such forward-looking statements are not guarantees of future perf= ormance and are subject to risks, uncertainties and assumptions which could= cause actual results to differ materially from those that may be implied b= y such forward-looking statements contained in this press release. Importan= t factors that could result in such differences include: changes in general= economic, business and competitive conditions, the inability to obtain nec= essary regulatory approvals or to obtain them on acceptable terms, costs as= sociated with research and development, changes in the prospects for produc= ts in the pipeline or under development by UCB, effects of future judicial = decisions or governmental investigations, product liability claims, challen= ges to patent protection for products or product candidates, changes in law= s or regulations, exchange rate fluctuations, changes or uncertainties in t= ax laws or the administration of such laws and hiring and retention of its = employees. UCB is providing this information as of the date of this press r= elease and expressly disclaims any duty to update any information contained= in this press release, either to confirm the actual results or to report a= change in its expectations. There is no guarantee that new product candidates in the pipeline will prog= ress to product approval or that new indications for existing products will= be developed and approved. Products or potential products which are the su= bject of partnerships, joint ventures or licensing collaborations may be su= bject to differences between the partners. Also, UCB or others could discov= er safety, side effects or manufacturing problems with its products after t= hey are marketed. Moreover, sales may be impacted by international and domestic trends toward= managed care and health care cost containment and the reimbursement polici= es imposed by third-party payers as well as legislation affecting biopharma= ceutical pricing and reimbursement. About Amgen Amgen is committed to unlocking the potential of biology for patients suffe= ring from serious illnesses by discovering, developing, manufacturing and d= elivering innovative human therapeutics. This approach begins by using tool= s like advanced human genetics to unravel the complexities of disease and u= nderstand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its biologi= cs manufacturing expertise to strive for solutions that improve health outc= omes and dramatically improve people=E2=80=99s lives. A biotechnology pione= er since 1980, Amgen has grown to be the world=E2=80=99s largest independen= t biotechnology company, has reached millions of patients around the world = and is developing a pipeline of medicines with breakaway potential.=C2=A0 For more information, visit www.amgen.com and follow us on www.twitter.com/= amgen. Amgen Forward-Looking Statements This news release contains forward-looking statements that are based on the= current expectations and beliefs of Amgen. All statements, other than stat= ements of historical fact, are statements that could be deemed forward-look= ing statements, including any statements on the outcome, benefits and syner= gies of the acquisition of Otezla^=C2=AE (apremilast), including anticipate= d Otezla sales growth and the timing of non-GAAP EPS accretion, as well as = estimates of revenues, operating margins, capital expenditures, cash, other= financial metrics, expected legal, arbitration, political, regulatory or c= linical results or practices, customer and prescriber patterns or practices= , reimbursement activities and outcomes and other such estimates and result= s. Forward-looking statements involve significant risks and uncertainties, = including those discussed below and more fully described in the Securities = and Exchange Commission reports filed by Amgen, including its most recent a= nnual report on Form 10-K and any subsequent periodic reports on Form 10-Q = and current reports on Form 8-K. Unless otherwise noted, Amgen is providing= this information as of the date of this news release and does not undertak= e any obligation to update any forward-looking statements contained in this= document as a result of new information, future events or otherwise. No forward-looking statement can be guaranteed and actual results may diffe= r materially from those Amgen projects. Discovery or identification of new = product candidates or development of new indications for existing products = cannot be guaranteed and movement from concept to product is uncertain; con= sequently, there can be no guarantee that any particular product candidate = or development of a new indication for an existing product will be successf= ul and become a commercial product. Further, preclinical results do not gua= rantee safe and effective performance of product candidates in humans. The = complexity of the human body cannot be perfectly, or sometimes, even adequa= tely modeled by computer or cell culture systems or animal models. The leng= th of time that it takes for Amgen to complete clinical trials and obtain r= egulatory approval for product marketing has in the past varied and Amgen e= xpects similar variability in the future. Even when clinical trials are suc= cessful, regulatory authorities may question the sufficiency for approval o= f the trial endpoints Amgen has selected. Amgen develops product candidates= internally and through licensing collaborations, partnerships and joint ve= ntures. Product candidates that are derived from relationships may be subje= ct to disputes between the parties or may prove to be not as effective or a= s safe as Amgen may have believed at the time of entering into such relatio= nship. Also, Amgen or others could identify safety, side effects or manufac= turing problems with its products, including its devices, after they are on= the market. Amgen's results may be affected by its ability to successfully market both = new and existing products domestically and internationally, clinical and re= gulatory developments involving current and future products, sales growth o= f recently launched products, competition from other products including bio= similars, difficulties or delays in manufacturing its products and global e= conomic conditions. In addition, sales of Amgen's products are affected by = pricing pressure, political and public scrutiny and reimbursement policies = imposed by third-party payers, including governments, private insurance pla= ns and managed care providers and may be affected by regulatory, clinical a= nd guideline developments and domestic and international trends toward mana= ged care and healthcare cost containment. Furthermore, Amgen's research, te= sting, pricing, marketing and other operations are subject to extensive reg= ulation by domestic and foreign government regulatory authorities. Amgen's = business may be impacted by government investigations, litigation and produ= ct liability claims. In addition, Amgen's business may be impacted by the a= doption of new tax legislation or exposure to additional tax liabilities. I= f Amgen fails to meet the compliance obligations in the corporate integrity= agreement between Amgen and the U.S. government, Amgen could become subjec= t to significant sanctions. Further, while Amgen routinely obtains patents = for its products and technology, the protection offered by its patents and = patent applications may be challenged, invalidated or circumvented by its c= ompetitors, or Amgen may fail to prevail in present and future intellectual= property litigation. Amgen performs a substantial amount of its commercial= manufacturing activities at a few key facilities, including in Puerto Rico= , and also depends on third parties for a portion of its manufacturing acti= vities, and limits on supply may constrain sales of certain of its current = products and product candidate development. Amgen relies on collaborations = with third parties for the development of some of its product candidates an= d for the commercialization and sales of some of its commercial products. I= n addition, Amgen competes with other companies with respect to many of its= marketed products as well as for the discovery and development of new prod= ucts. Further, some raw materials, medical devices and component parts for = Amgen's products are supplied by sole third-party suppliers. Certain of Amg= en's distributors, customers and payers have substantial purchasing leverag= e in their dealings with Amgen. The discovery of significant problems with = a product similar to one of Amgen's products that implicate an entire class= of products could have a material adverse effect on sales of the affected = products and on its business and results of operations. Amgen's efforts to = acquire other companies or products and to integrate the operations of comp= anies Amgen has acquired may not be successful. A breakdown, cyberattack or= information security breach could compromise the confidentiality, integrit= y and availability of Amgen's systems and Amgen's data. Amgen's stock price= may be volatile and may be affected by a number of events. Amgen's busines= s performance could affect or limit the ability of the Amgen Board of Direc= tors to declare a dividend or its ability to pay a dividend or repurchase i= ts common stock. Amgen may not be able to access the capital and credit mar= kets on terms that are favorable to it, or at all. The scientific information discussed in this news release related to Amgen'= s product candidates is preliminary and investigative. Such product candida= tes are not approved by the European Medicines Agency, and no conclusions c= an or should be drawn regarding the safety or effectiveness of the product = candidates. =C2=A0 GenericFile SmPC ema-combined FINAL (https://u7061146.ct.sendgrid.net/wf/click?upn=3DG6= 2jSYfZdO-2F12d8lSllQBx1W27HkUdGSImvHQ6HnxefH6vFiGPeqeb84i0MpatjMiEkYzxzLJ6e= XI5HI-2F95JP23-2B1tyE0YLH-2BGrIcTsVXs0-3D_-2B-2Ft0TnE1oEbVIWS8vHM8JK8eu8RpJ= 4re5BwmFRw6Tr0XlsWOeqQqZTjzwcPKItQR0hTxd9ZQ7rBLYSOuAKeTefElHQ9EZfLoWbvi8z1T= sABlR759s4J2EhtSfn3pHAUtByXw7JC3JPLCZWALTfp2qB8ybKI-2BIfr9CYvKg-2FmYTIW0h1m= kdOStEe585hP9OLwIBCqoYPYNvvVTHJplwfHevNDml4kDIXLkxgK-2B9D7uSwvLNiKTg7XQK0Xz= gK81PNgZncnIA4QEeLKC-2BJBC0eR8UdragWkC31ghVOLbVQ4FKsxKGES19k-2B6kd-2FTdaD0Y= sCe-2BYkyuxSrM1DtzuHzKxy1GNwziVRjdCpiLaKgw3JHETw-3D GenericFile EVENITY EU Commission Approval Press Release (https://u7061146.ct.sendgrid.= net/wf/click?upn=3DG62jSYfZdO-2F12d8lSllQBx1W27HkUdGSImvHQ6HnxefH6vFiGPeqeb= 84i0MpatjMZWCh1yTKM0gHQZqYJ3nNFKohzfRox7GSOBmAqhW3IEk-3D_-2B-2Ft0TnE1oEbVIW= S8vHM8JK8eu8RpJ4re5BwmFRw6Tr0XlsWOeqQqZTjzwcPKItQR0hTxd9ZQ7rBLYSOuAKeTefElH= Q9EZfLoWbvi8z1TsABlR759s4J2EhtSfn3pHAUtByXw7JC3JPLCZWALTfp2qB8ybKI-2BIfr9CY= vKg-2FmYTIW0h1mkdOStEe585hP9OLwIBCqoYPYNvvVTHJplwfHevP9LjZNd3AsQVvS-2FvNoqB= 1839RKtHacPU9ZONBYIzIEsHVgqhGyYz37vzWk-2BCZOZKWTE0V6jDfhsLxuRerBuUGvq-2BWtg= aADQmd1Vs3uals71qEOfRd0XRpCv4h7pO3u-2FTZaStWGZiQ6vEfVpDyIIiDI-3D=0D =0D ______________________=0D If you would rather not receive future communications from UCB SA, please g= o to https://u7061146.ct.sendgrid.net/wf/click?upn=3DG62jSYfZdO-2F12d8lSllQ= Bz2p53T0v-2BoEIvbo6vDi8C-2BOyFzyb6obo-2BzKSgNKq4mrb3GIB59jB8d-2FrDmzRBsOGI-= 2F1O37veZF3wrtUFg1Z3V8exx-2FCBgYDEtUM-2FcD1zK2ICbY6M-2BCjh8ktu-2FXxFaV0DTl4= aovucbGX8yh1eLQkGpc-3D_-2B-2Ft0TnE1oEbVIWS8vHM8JK8eu8RpJ4re5BwmFRw6Tr0XlsWO= eqQqZTjzwcPKItQR0hTxd9ZQ7rBLYSOuAKeTefElHQ9EZfLoWbvi8z1TsABlR759s4J2EhtSfn3= pHAUtByXw7JC3JPLCZWALTfp2qB8ybKI-2BIfr9CYvKg-2FmYTIW0h1mkdOStEe585hP9OLwIBC= qoYPYNvvVTHJplwfHevElxC33yuCNW1KYAIMheAXzBtGH2aJxl8HIO8ftS50FUUMI2SckwQZfDz= uKtNXGj3diB2Wwviw7gSlO2y73oOvRnBRofS7TYh4tLbTFoWWbXrZRhxddKkHZJ08uQMOLOSsOU= oNiYBmC4F24wNiB7Ny8-3D=0D UCB SA, All=C3=A9e de la Recherche, 60 ., Brussels, . B - 1070 Belgium=

24/02/2020 20:00
20/02/2020 07:00
14/02/2020 20:01
10/02/2020 20:00
31/01/2020 20:01
28/01/2020 07:01
27/01/2020 20:00
20/01/2020 20:10
20/01/2020 20:05
20/01/2020 20:01